Rigel Pharmaceuticals, Inc. (RIGL) Financials
RIGL Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 117.2 million | 145.9 million |
2023-09-30 | 115.3 million | 147.2 million |
2023-06-30 | 117.1 million | 145.2 million |
2023-03-31 | 123.6 million | 147.9 million |
RIGL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -6.4 million | 1.9 million |
2023-09-30 | -1.4 million | 1.9 million |
2023-06-30 | 5.9 million | 2.2 million |
2023-03-31 | -19.1 million | 2.8 million |
RIGL Net Income
No data available :(
RIGL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 56.9 million | - | 977000 |
2023-09-30 | 62.4 million | - | 1.1 million |
2023-06-30 | 64.4 million | 59.6 million | 1.1 million |
2023-03-31 | 58.7 million | 59.5 million | 1.3 million |
RIGL Shares Outstanding
RIGL Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 110000 | 3.2 million | 26.9 million | - |
2023-09-30 | 22000 | 6.5 million | 24.9 million | - |
2023-06-30 | - | 4.8 million | 26.3 million | - |
2023-03-31 | 15.0 million | 10.1 million | 27.7 million | - |
RIGL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 35.8 million | 3.8 million |
2023-09-30 | 28.1 million | 1.3 million |
2023-06-30 | 26.9 million | 1.1 million |
2023-03-31 | 26.1 million | 977000 |
RIGL
Price: $1.22
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.14 USD
P/E Ratio: -8.71
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 2.8 million
Ebitda: -17.7 millionMarket Capitalization: 214.0 million